News | Radiopharmaceuticals and Tracers | July 07, 2016

Cell>Point Executes China License for Oncardia Diagnostic Imaging Agent

Agreement with United Eastern Pharmaceutical brings agent for cancer and heart disease imaging to China, Hong Kong and Macau

Cell>Point, license agreement, China, United Eastern Pharmaceutical, Oncardia imaging agent

July 7, 2016 — Cell>Point announced in mid-June it has entered into an exclusive license agreement for China, Hong Kong and Macau with United Eastern Pharmaceutical (UEP), a company representing a consortium from the United States and China. The license agreement covers Cell>Point’s diagnostic radiopharmaceutical Oncardia (ethylenedicysteine-glucosamine) which was developed for labeling with technetium-99m for single photon emission computed tomography (SPECT) cameras or 68-gallium for positron emission tomography (PET) cameras for imaging in cancer and cardiovascular disease.

Oncardia is based on an ethylenedicysteine drug conjugate platform licensed by Cell>Point from The University of Texas MD Anderson Cancer Center. The license with UEP provides for Cell>Point to receive an upfront payment and regulatory milestone payments as well as royalties on sales. Cell>Point will be seeking regulatory approval from the China Food and Drug Administration (FDA) to expand its Phase 3 lung cancer imaging trial to include clinical sites in China. The parties have agreed that when the current cardiovascular study reaches Phase 3, Cell>Point will include China clinical sites as part of the study.

According to Haoran Xi, CEO of UEP, “China needs affordable and accessible diagnostic molecular imaging to reach a substantially larger universe of people than is presently the case with the current standard of care. Plans are to pursue approvals in diagnosing and staging lung, head and neck, colorectal, breast, liver, stomach, lymphoma and other cancers in addition to diagnosing the presence and extent of cardiac ischemia. Oncardia can be used to assess the patient’s response to therapy while undergoing therapy. This will give oncologists a valuable tool to determine if the patient is benefiting from the selected therapy or should the oncologist reconsider the choice of therapy. The Chinese Central Government is implementing programs to improve the quality of medical care throughout the country. Cancer and vascular disease are the leading causes of death in China.”

Oncardia was developed to address the limitations of FDG-PET (positron emission tomography) in cancer imaging while increasing access to cancer imaging to a significantly greater number of hospitals worldwide. Cell>Point is completing a Phase 3 trial for Oncardia in lung cancer under a Letter of Agreement with the FDA pursuant to a Special Protocol Assessment, and a Phase 2b cardiovascular trial in patients with coronary artery disease. The focus in cardiology is to assess the patient’s ischemia in a rest-only imaging procedure which will dramatically shorten the time required to complete the patient’s study and achieve noticeably greater diagnostic accuracy compared to the standard of care.

For more information: www.cellpointweb.com

Related Content

Study Explores Magnetic Nanoparticles as Bimodal Imaging Agent for PET/MRI

Image courtesy of MR Solutions.

News | PET-MRI | May 23, 2019
Researchers from Bourgogne University in Dijon, France, showed that use of superparamagnetic iron oxide nanoparticles (...
Life Image and Bialogics Analytics Partner to Deliver Imaging Business Intelligence
News | Analytics Software | May 21, 2019
Life Image and business intelligence analytics provider Bialogics Analytics have formed a strategic partnership that...
New Phase 2B Trial Exploring Target-Specific Myocardial Ischemia Imaging Agent
News | Radiopharmaceuticals and Tracers | May 17, 2019
Biopharmaceutical company CellPoint plans to begin patient recruitment for its Phase 2b cardiovascular imaging study in...
3 Recommendations to Better Understand HIPAA Compliance
Feature | Information Technology | May 17, 2019 | Carol Amick
According to the U.S.
Blue Earth Diagnostics Expands Access to Axumin in Europe
News | Radiopharmaceuticals and Tracers | May 13, 2019
Blue Earth Diagnostics announced expanded access to the Axumin (fluciclovine (18F)) imaging agent in Europe. The first...
Shine Medical Technologies Breaks Ground on U.S. Medical Isotope Production Facility

Image courtesy of Amen Clinics

News | Radiopharmaceuticals and Tracers | May 10, 2019 | Jeff Zagoudis, Associate Editor
Shine Medical Technologies Inc. broke ground on their first medical isotope production facility in Janesville, Wis. U.S...
ITN reached 90,000 unique Facebook users with content during the week of the visit to Central DuPage Hospital

ITN reached 90,000 unique Facebook users with content during the week of the visit to Central DuPage Hospital.

News | Radiology Business | May 10, 2019
Imaging Technology News (ITN) earned an Honorable Mention at the 2019 National Azbee Awards of Excellence in the Cross-...
An illustration of radiology department analytics data showing GE Healthcare's business analytics software.
Feature | Radiology Business | May 03, 2019 | April Wilson
According to IBM, the world creates 2.5 quintillion bytes of data daily.
Fail-safe Program for New Medical Technology Focuses on Patient Safety
News | Radiology Business | April 29, 2019
New medical technology offers the promise of improving patient care, as well as the potential for harm if caregivers...